BD is oxidized by cytochrome P450 enzymes, forming the mutagenic epoxide metabolites 3,4-epoxy-1-butene (EB), 1,2,3,4-diepoxybutane (DEB) and 1,2-epoxy-3,4-butanediol (EBD). 3, 4 . The epoxides can form adducts with macromolecules such as DNA and proteins. Protein adduct formation is considered to be a valuable surrogate for DNA adducts for biological monitoring of exposure. Several studies have been performed to characterize adducts formed between hemoglobin (Hb) and the metabolites EB and DEB. Human Hb [5] [6] [7] as well as mouse Hb 8, 9 has been studied. However, no studies have been performed for the structural characterization of adducts between any of the butadiene metabolites and HSA. This protein is the most prevalent protein of the blood plasma with an approximate half-life of 21 days. It has a variety of functions including the binding and transport of numerous endogenous substrates and xenobiotics.
The purpose of the present study was to determine the binding sites of the THB adducts with HSA formed by in vitro alkylation with high molar ratios of EBD. These results were then used to develop a more sensitive SRM based LC/MS method that was used to determine which adducted peptides that yielded the highest responses when lower molar ratios of EBD were used.
MATERIALS AND METHODS
Caution: EBD is hazardous and a potential carcinogen and must be handled with proper safety measures. Destruction of the epoxide was performed using 1 M HCl.
Chemicals and Materials
EBD was synthesized by epoxidation of 3-butenediol, the product consisted of two stereoisomers and the purity was 98 % determined by NMR (Synthelec AB, Lund, Sweden).
Cesium Iodine (CsI) was purchased from Acros Organics (Geel, Belgium) and sex pheromone inhibitor iPD1 was obtained from Bachem (Bubendorf, Switzerland 
Instrumentation
For the characterization of the peptides a nanoelectrospray source (nanoES) on a hybrid quadropole-time-of-flight mass spectrometer (QqTOFMS; Q-STAR, Applied Biosystems, Foster City, CA) was used. The mass spectrometer was calibrated daily using CsI (m/z 132.9054) and the pentapeptide sex pheromone inhibitor iPD1 (m/z 829.5398). The data was evaluated using Analyst QS software with BioAnalyst TM extensions, supplied by Applied
Biosystems. For increased sensitivity the digests were analyzed in SRM mode using triple quadrupole mass spectrometry with ESI on a turbo ionspray source (API 3000, Applied
Biosystems) coupled to a liquid chromatography system from Perkin Elmer (Norwalk, Connecticut, USA; LC/MS).
In-silico tryptic digests of HSA
The sequence of HSA used in this study corresponds to the sequence entry in Swiss-Prot:
P02768 without the first 24 N-terminal amino acids. The HSA sequence used has a monoisotopic molecular weight of 66429 Da and consists of 585 amino acids. The theoretical m/z of the tryptic digest products of HSA and the MS/MS fragment ion series of tryptic peptides were obtained using tools in the Analyst QS software. Lists showing the theoretical m/z for the tryptic peptides were made using the software. The lists included various charge states of peptides, tryptic miss cleavages and the number of adducts. These lists were used as an aid in the identification of adducted peptides. The 79 theoretical tryptic peptides of HSA were abbreviated in sequence from T1 to T79. The nomenclature used was proposed by
Roepstorff and Fohlman
10
.
In-vitro synthesis of HSA-EBD conjugates
Purified HSA (fraction V) was used in the synthesis of the conjugates. EBD and HSA were dissolved in PBS pH 7.4. Different volumes of the EBD-solution were added to 1 mL of HSA solution (4 mg) and molar ratios of 1:600, 1:1 and 1:0.1 (HSA:EBD) were achieved. The solutions were incubated at 37 °C for 5 days. A blank HSA sample was also prepared in PBS buffer and incubated under the same conditions. To remove reactive EBD, the samples were dialyzed (cutoff 3 500 Da) against PBS buffer for seven days with five changes of buffer before further use. The dialysis time was chosen according to Rosqvist et al. 11 .
Reduction of conjugates
HSA contains 17 disulphide bonds and to obtain a more efficient digest as well as to prevent regeneration of disulphide bridges after trypsination, the conjugates and the blank HSA were reduced and carboxyamidomethylated. Four mg of the HSA-EBD conjugates and blank the HSA in 0.2 ml 50 mM NH 4 HCO 3 was mixed with 0.4 ml DTT (12 mg/ml) at 55°C for 1 h.
The proteins were then carboxyamidomethylated with 0.4 ml iodoacetamid (25 mg/ml) in darkness, at room temperature for 30 min. The solutions were dialyzed against 50 mM NH 4 HCO 3 overnight to remove excess reagent.
Digestion of HSA-EBD and HSA with trypsin
Enzymatic digestion using trypsin was performed both on the conjugates and on the blank HSA. Trypsin was dissolved in 0.1 M NH 4 HCO 3 (pH 8.8) and added at a ratio of 1:50.
Incubation was performed at 37°C overnight followed by evaporation to dryness. The samples were stored at -20°C until further use. 
NanoES QqTOFMS analysis of tryptic digests
The tryptic digests of EBD-conjugated HSA and blank HSA that had been fractionated by preparative LC were analyzed for adducts using nanoES QqTOFMS in the scanning MS mode and the MS/MS mode. The peptides in each fraction were dissolved in 30 μL of water. Prior to analysis, 10 μL of the fractions were acidified with 3 μL TFA (2.5% in water). The samples were purified and concentrated using ZipTipC 18 pipette tips. The samples were eluted with 2 μL 75% methanol/10% formic acid/ 15% water directly into the nanospray needle.
Adducted peptides were identified by comparison with the corresponding fraction for blank HSA and by comparison with lists of theoretical tryptic peptides of HSA both with and without adducts. Tandem mass spectrometry sequencing was used to confirm the adducted peptides identity and to identify which amino acid residue was adducted.
LC/MS
The tryptic peptides were also analyzed with a more quantitative approach using LC/MS in SRM mode. The peptides were separated on a Genesis C 18 column (2.1 mm i.d. × 50 mm;
Jones Chromatography, Lakewood, CO, USA) with a mobile phase consisting of A: water and B: methanol, both containing 0.5% acetic acid. Separation was performed using a linear gradient between 5% and 100% B in 15 min. The injection volume was 20 μL and the flow rate was 0.2 mL min -1 . The temperature of the auxiliary gas was set to 420 °C and the ion spray voltage to 5000 V. Pure nitrogen was used as nebulizer, auxiliary, curtain, and collision gas.
A tryptic digest of the conjugate HSA-EBD 1:600 was used to tune the mass spectrometer for THB-adducted HSA peptides and m/z transitions were selected for each adducted peptide in accordance with mass spectrometric data obtained from QqTOFMS analyses. In the first step a Q1 scan was performed to select the doubly or triply charged ions for each identified adducted peptide. In a second step, a product ion scan was performed for each of the 23 tryptic peptides in order to select the fragments with the highest intensity in the y-or b-series ions. In the third step a SRM method was created and the collision energies, focusing and the declustering potentials were optimized by infusion of the HSA-EBD conjugate 1:600. The analyses were performed with SRM in the positive ion mode and with a dwell time of 20 ms.
Alternate injections of methanol were made to exclude the risk of carry over-effects. Blank HSA digests were also injected to ensure that the adducted peaks originated from EBDconjugation. Once the parameters were optimized, digests of blank HSA and HSA adducted with molar ratios of 1:1 and 1:0.1 (HSA:EBD) were analyzed with the LC/MS method.
RESULTS

NanoES QqTOFMS analysis of tryptic digests
When digesting the conjugate and the blank HSA a large number of peptides are formed. A strong ion suppression effect could be noted if crude digest was subjected to nanoES
QqTOFMS. In order to facilitate the evaluation of the peptides the digest mixtures were fractionated using preparative LC. Each fraction was then subjected to nanoES QqTOFMS analysis. TOF spectra were generated for each conjugate fraction and the data were compared with the corresponding fraction from a blank HSA digest. Peptides observed with an addition of m/z 104, or a multiple of 104, corresponding to one or several THB adducts, were subjected to MS/MS. To identify the site of modification on the peptides and to confirm the sequence of a suspected adducted peptide, product ion analyses were carried out. The fragment series ions were used to elucidate which amino acid in the peptide sequence that EBD had bound to. The b-and/or y-series ions and immonium ions were the most prominent ions observed.
Typical MS/MS spectra of adducted peptides are shown in figures 1 and 2. The * denotes the modification sites of the peptides. In the HSA-EBD conjugate (1:600), a total of 26 THB adducted tryptic peptides were found (Table 1) . No multiple adducts were observed in this study.
The identification of the modification site of an adduct on the peptide T45-46 ( 
Glutamic acid adducts
Six adducted glutamic acid residues could be found in total. However, only three adducted peptides were observed. Each of these peptides had two reactive glutamic acids in the sequence. The analyzed peptides were a mixture of two adducted peptides with both sites adducted but not both simultaneously. All product ion spectra of peptides with adducted glutamic acid residues showed the immonium ion, Glu-THB at m/z 206. 
LC/MS analysis of tryptic digests
Tryptic peptides from an HSA-EBD conjugate 1:600 were used to tune the LC/MS instrument. A Q1 scan was performed to compare the charge state of the peptides with the results from the QqTOFMS analysis. It was found that the highest signal was obtained for the peptides in the same charge state as obtained when using the QqTOFMS instrument (data not shown). In the second step, product ion scans were performed for each of the 23 tryptic peptides in order to select the fragments ions with the highest response. The collision energy was initially chosen for each peptide based on charge state, peptide length and experience from the QqTOFMS analysis. In the third step, a SRM method was created. The SRM method consisted of 59 transitions, each with a dwell time of 20 msec. This entails 1.47s for each scan cycle corresponding to about 10-12 data points for each peak. The collision energies, focusing and the declustering potentials were optimized by ramping the potentials for each parameter during a constant infusion of the HSA-EBD conjugate 1:600.
After the MS parameters were optimized, the peptides were analyzed in SRM mode. The peptides were separated using a 5 cm C 18 column using a 15 min gradient. The method was then applied on tryptic peptides from a digested blank HSA, HSA-EBD conjugate 1:600, 1:1 and 1:0.1. The detection limit was defined using the conjugate 1:0.1 and the blank HSA digests. The response of the peaks in the 1:0.1 conjugate had to at least three times the noise level observed at the same retention time in a blank HSA digest. Also, the response had to be higher than a signal/noise ratio of 3/1 within the chromatogram in the conjugate 1:0.1. 
DISCUSSION
This study shows that EBD forms THB adducts with HSA in vitro. Adducted tryptic peptides and THB adduct positions were initially identified with nanoES-QqTOFMS. The information obtained in these experiments was then used to set up an LC/MS analysis where SRM was used to detect adducted peptides. NanoES QqTOFMS proved to be a powerful tool for identification of the modification sites. The small sample consumption when using nanospray allows MS and MS/MS experiments to be performed during periods of time of up to several hours. When identifying modification sites in peptides from MS/MS spectra, many data points are often necessary to produce detailed spectra that are easily interpretable. Furthermore, fragmentation parameters e.g. collision energy, often has to be varied between peptides to obtain a spectra of high quality that demonstrates clear fragment series ions. Thus, nanoES was more convenient in this study, compared to on-line LC analysis, for the identification of modification sites. The drawback is the time consumption. On the other hand LC/MS/MS with SRM provided higher sensitivity, which was necessary when the 1:1 and 1:0.1 conjugates were analysed.
The initial identification of adducted peptides was achieved by comparing full scan mass spectra of corresponding fractions of tryptic digest of EBD-HSA and blank HSA. At this stage 1:600 HSA:EBD conjugates were used. Mass spectrometric peaks that displayed a mass difference of 104 or a multiple of 104 between corresponding fractions were subjected to MS/MS in order to identify the peptide and the adducted amino acid moieties. A total of 26 THB adducts were identified on 23 tryptic peptides in the HSA-EBD conjugate (Table 1) .
Product ion spectra were used to identify the sites of modification on the peptides and to confirm the sequence of suspected adducted peptides. The fragment series ions were used to pinpoint the site of adduction. The b-and/or y-series ions and immonium ions were the most useful ions when determining the site of modification. The software also provided theoretical fragment series ions that were useful when confirming adducted peptides.
The adducted glutamic acid residues and adducted histidine residues provided immonium ions upon fragmentation, which facilitated the determination of the adduction sites. Lysine, on the other hand did not provide immonium ions. However, the trypsin was not able to cleave the protein at adducted lysine residues. Thus, all peptides with adducted lysine residues consisted of two adjacent tryptic peptide sequences. This was helpful in identifying lysine adducts modification sites. Similar miscleavages have also been observed in other studies 9, 12 .
The amino acids found to carry THB adducts at physiological pH were the N-terminal aspartic acid residue, glutamic acid residues, histidine residues, and lysine residues.
At a molar ratio of 1:0.1 (HSA:EBD) THB adducts could be found on the amino acids, Glu .
Several studies have shown that the n-terminal valine of Hb reacts readily with EB, DEB and EBD. Adducts to the n-terminal valine of Hb has been used as a biomarker for exposure to BD [23] [24] [25] [26] [27] [28] . In our study, the n-terminal Asp of HSA was found to carry an THB adduct at molar ratios of 1:600 (HSA:EBD). However, at molar ratios of 1:1 and 1:0.1 (HSA:EBD) THB adducts could not be observed even when using LC/MS in SRM mode. This may indicate that the n-terminal Asp in HSA is less reactive than the n-terminal Val of Hb. This has also been observed in other studies of reactive compounds with a quantitative approach and concerning both Hb and HSA 21, 29 .
As mentioned above, BD is metabolized to three reactive epoxides. Adduct formation of the other two reactive metabolites, EB and DEB [5] [6] [7] [8] has been studied using similar approaches using Hb. It would be reasonable to expect these epoxides to react with similar amino acid moieties as EBD. Moll et al. 8 studied adduct formation of EB to mouse Hb. Adducts were found bound to Val, His and Lys in this study whereas no cystein adducts were observed. In a study of adduct formation of DEB to human Hb by Basile et al. 6 no Lys adducts were found however they did find Val, His, Glu and Cys adducts. Miraglia et al. 5 identified Val, His and
Cys adducts of DEB in human Hb. Also Badghisi et al. 7 identified Val and Cys adducts of DEB in human Hb. In all studies the n-terminal valine was identified as a main site of adduction. Clearly, these studies are not in complete agreement, however one should keep in mind that the different epoxides and the different HBs may not react in exactly the same way.
Differences in the findings may also depend on differences in the amino acid sequence in the proteins. Adjacent amino acids or the protein confirmation may affect the formation of adducts. Also differences in experimental conditions used during alkylation, e.g. pH could affect the adduct formation. In a study of interactions between peptides and DEB by Cech et al. 30 DEB was found to be mostly reactive to Arg, when the synthesis was performed in 0.1 M NaOH. Despite the differences between these studies, all the adducted amino acid moieties identified in this study (Glu, His and Lys) have previously been found to carry adducts. No
Cys adducts were observed in this study although Cys residues in HSA and Hb have been shown to be reactive towards epoxides. The THB adducts to Cys are likely to be stable.
However, the reduction of HSA followed by the carboxyamidomethylation could affect the stability of the THB adduct. If this step was omitted the trypsination was inefficient. (data not shown)
When characterizing the adducts formed between to HSA and EBD using nanoESQqTOFMS, high molar ratios between HSA and EBD was required in order to achieve interpretable spectra. In a previous study by Basile et al. 6 there appears to be a higher response for peptides with THB adducts compared to our study. In that study the molar ratio was 1:10 (HSA:DEB) and the reaction time was shorter. Thus the modification rate in our study appears to be low. It is, however, difficult to judge if the sensitivity is due to a low modification rate of the epoxide to HSA or if the THB adducted peptides provide a low response in the mass spectral analysis. It is also possible that DEB is more reactive than EBD.
The studied adducts can be considered to be stable both from a chemical and a mass spectrometric standpoint. The reaction was allowed to take place for a five-day period at 37 °C followed by 7 days of dialysis. Chemically unstable adducts and reactive epoxides would likely to have been removed during this treatment.
Although quantification of these peptides was beyond the scope of this investigation, it was surmised that these peptides were the most reactive towards EBD at physiological pH.
Ultimately, the LC/MS method would be an attractive analytical method for biological monitoring of exposure to BD. Unfortunately, the in vitro conjugates used in this study corresponds to unrealistically high exposure levels as compared to what can be found in vivo after BD exposure. Recently, Boysen et al. employed an immunoaffinity sample preparation column to selectively trap and enrich a cyclic n-terminal DEB adduct 31 . Using a similar immunoaffinty column for sample enrichment it would be feasible to use the LC/MS method for biological monitoring.
CONCLUSIONS
This study shows that THB adducts are formed with HSA after reaction with EBD in vitro.
Conjugates between HSA and EBD were characterized using nanoES-QqTOFMS. For increased sensitivity a LC/MS method using SRM was applied. At a molar ratio of 1:0.1 
